BTIG Believes Loxo Oncology (NASDAQ: LOXO) Still Has Room to Grow

By Jason Carr

BTIG analyst Dane Leone maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO) yesterday and set a price target of $156. The company’s shares closed yesterday at $139.50, close to its 52-week high of $143.62.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.6% and a 70.6% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and Blueprint Medicines.

Currently, the analyst consensus on Loxo Oncology is Strong Buy and the average price target is $149.33, representing a 7.0% upside.

In a report issued on May 8, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $143.62 and a one-year low of $43.34. Currently, Loxo Oncology has an average volume of 398.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Loxo Oncology, Inc. is a biopharmaceutical company, which develops small molecule therapeutics for the treatment of cancer. Its pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.